3 April 2004

Contents

Editorial

• Volume 5 number 3 April 2004

Treatment alerts

• Risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine

Conference reports

• 11th Conference on Retroviruses and Opportunistic Infections (CROI)

• Drug levels can persist for more than two weeks after stopping efavirenz

• Race affects absorption and clearance of efavirenz

• Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination

• Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome

• Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T

• COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation

• Studies of new pipeline drugs

• Little benefit seen for treatment during acute infection

• Summary of resistance studies at Retrovirus

• Update on peripheral neuropathy in HIV-infection

• Smoking marijuana provides analgesic effect on HIV neuropathy

• Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure

• Low-dose rHGH maintains reductions in abdominal fat for 60 weeks